Nickel JC. Placebo therapy of benign prostatic hyperplasia: a 25-month study.
Br J Urol. 1988;81:383 - 387.
Braeckman J. The extract of
Serenoa repens
in the treatment of benign prostatic hyperplasia: a multicenter open study.
Curr Ther Res. 1994;55:776 - 785.
Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with
Sabal serrulata
for one year.
Int Urol Nephrol. 1993;25:565 - 569.
Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
J Urol.
2000;163:1451 - 1456.
Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2-7, 2001; Anaheim, Calif.
Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate (Permixon) [in Italian].
Urologia. 1983;50:1042 - 1048.
Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant
Serenoa repens
in benign prostatic hyperplasia.
BrJ Clin Pharmacol. 1984;18:461 - 462.
Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomatology caused by prostatic adenoma using an extract of
Serenoa repens. Double-blind clinical study vs. placebo [in Italian].
Minerva Urol Nefrol. 1985;37:87 - 91.
Boccafoschi C, Annoscia S. Comparison of
Serenoa repens
extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian].
Urologia. 1983;50:1257 - 1268.
Smith HR, Memon A, Smart CJ, et al. The value of Permixon in benign prostatic hypertrophy.
Br J Urol. 1986;58:36 - 40.
Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders.
Clin Drug Invest. 1995;9:291 - 297.
Mattei FM, Capone M, Acconcia A, et al.
Serenoa repens
extract in the medical treatment of benign prostatic hypertrophy [in Italian].
Urologia. 1988;55:547 - 552.
Plosker GL, Brogden RN.
Serenoa repens
(Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Drugs Aging. 1996;9:379 - 395.
Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Prostate. 1996;29:231 - 240.
Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent(Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benignprostatic hyperplasia: a one-year randomized international study.
Eur Urol.
2002;41:497-507.
Bach D. Medikamentose Langzeitbehandlung der BPH. Ergebnisse einer prospektiven 3-Jahres-Studie mit dem Sabalextrakt IDS 89.
Urologe [B]. 1995;35:178 - 183.
Bach D, Schmitt M, Ebeling L. Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH).
Phytomedicine. 1997;3:309 - 313.
Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
BJU Int. 2000;86:439 - 442.
Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
J Urol.
2000;163:1451 - 1456.
Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.
Urology. 2001;58:960 - 964.
Braeckman J, Bruhwyler J, Vandekerckhove K, et al. Efficacy and safety of the extract of
Serenoa repens
in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms.
Phytother Res.
1997;11:558 - 563.
Stepanov VN, Siniakova LA, Sarrazin B, et al. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
Adv Ther. 1999;16:231 - 241.
Plosker GL, Brogden RN.
Serenoa repens
(Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Drugs Aging. 1996;9:379 - 395.
Plosker GL, Brogden RN.
Serenoa repens
(Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Drugs Aging. 1996;9:379 - 395.
Bach D, Schmitt M, Ebeling L. Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH).
Phytomedicine. 1997;3:309 - 313.
Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature.
J Intern Med. 2001;250:167-169.
Giannakopoulos X, Baltogiannis D, Giannakis D, et al. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens.
Adv Ther. 2002;19:285 - 296.
Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease.
J Urol. 2002;168:150 - 154; discussion 154.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.